HC Wainwright Brokers Increase Earnings Estimates for ARQT

Key Points

• HC Wainwright has increased its earnings estimates for Arcutis Biotherapeutics, projecting a Q3 2026 EPS of $0.00, up from a previous estimate of ($0.01).
• The company's recent earnings report showed a smaller loss than expected, with an EPS of ($0.13), surpassing the consensus estimate of ($0.18) by $0.05.
• Analysts have a consensus rating of "Moderate Buy" for Arcutis, with a target price of $19.80, indicating positive sentiment among equities analysts.

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) - Equities research analysts at HC Wainwright increased their Q3 2026 earnings per share (EPS) estimates for Arcutis Biotherapeutics in a research report issued to clients and investors on Thursday, August 7th. HC Wainwright analyst D. Tsao now forecasts that the company will earn $0.00 per share for the quarter, up from their prior forecast of ($0.01). The consensus estimate for Arcutis Biotherapeutics' current full-year earnings is ($1.33) per share. HC Wainwright also issued estimates for Arcutis Biotherapeutics' Q4 2026 earnings at $0.22 EPS, FY2028 earnings at $1.94 EPS and FY2029 earnings at $2.48 EPS.

Arcutis Biotherapeutics (NASDAQ:ARQT - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($0.13) earnings per share for the quarter, topping analysts' consensus estimates of ($0.18) by $0.05. Arcutis Biotherapeutics had a negative return on equity of 61.25% and a negative net margin of 35.40%. The company had revenue of $81.50 million for the quarter, compared to analyst estimates of $72.70 million.

Several other equities analysts have also weighed in on ARQT. Needham & Company LLC boosted their target price on shares of Arcutis Biotherapeutics from $20.00 to $22.00 and gave the company a "buy" rating in a report on Thursday. Cowen reiterated a "buy" rating on shares of Arcutis Biotherapeutics in a report on Thursday. Finally, The Goldman Sachs Group started coverage on Arcutis Biotherapeutics in a research note on Friday, July 25th. They set a "neutral" rating and a $18.00 target price for the company. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $19.80.

Arcutis Biotherapeutics Trading Down 1.0%

Shares of ARQT stock traded down $0.14 on Friday, hitting $13.98. 1,015,489 shares of the stock traded hands, compared to its average volume of 2,142,088. The company has a debt-to-equity ratio of 0.75, a quick ratio of 3.37 and a current ratio of 3.55. Arcutis Biotherapeutics has a twelve month low of $8.03 and a twelve month high of $17.75. The firm's 50-day moving average price is $14.26 and its two-hundred day moving average price is $14.14. The stock has a market capitalization of $1.67 billion, a PE ratio of -18.65 and a beta of 1.84.

Institutional Investors Weigh In On Arcutis Biotherapeutics

Large investors have recently added to or reduced their stakes in the business. Point72 Asset Management L.P. raised its holdings in Arcutis Biotherapeutics by 617.5% in the fourth quarter. Point72 Asset Management L.P. now owns 1,753,522 shares of the company's stock valued at $24,427,000 after acquiring an additional 1,509,136 shares in the last quarter. Paradigm Biocapital Advisors LP purchased a new stake in shares of Arcutis Biotherapeutics in the 1st quarter valued at approximately $22,918,000. Cercano Management LLC acquired a new stake in shares of Arcutis Biotherapeutics in the 4th quarter valued at $17,487,000. Millennium Management LLC raised its holdings in shares of Arcutis Biotherapeutics by 101.3% in the 4th quarter. Millennium Management LLC now owns 2,310,163 shares of the company's stock valued at $32,181,000 after purchasing an additional 1,162,690 shares in the last quarter. Finally, Driehaus Capital Management LLC purchased a new stake in shares of Arcutis Biotherapeutics during the 4th quarter worth $15,278,000.

Insider Transactions at Arcutis Biotherapeutics

In related news, insider Masaru Matsuda sold 6,330 shares of the firm's stock in a transaction dated Monday, August 4th. The stock was sold at an average price of $14.33, for a total transaction of $90,708.90. Following the completion of the transaction, the insider directly owned 197,364 shares in the company, valued at $2,828,226.12. This trade represents a 3.11% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Patrick J. Heron purchased 2,646 shares of the business's stock in a transaction on Friday, June 13th. The shares were acquired at an average price of $13.08 per share, for a total transaction of $34,609.68. Following the completion of the purchase, the director directly owned 27,448 shares of the company's stock, valued at approximately $359,019.84. This trade represents a 10.67% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders have acquired 7,434 shares of company stock worth $99,277 and have sold 78,728 shares worth $1,136,027. Company insiders own 9.40% of the company's stock.

Arcutis Biotherapeutics Company Profile

Arcutis Biotherapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.